Evolus, INC. (EOLS) — SEC Filings

Q: What are the key financial highlights for Evolus, INC.?

Key financial highlights for Evolus, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Evolus, INC.?

Key executives at Evolus, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Evolus, INC. stock?

Risk factors for Evolus, INC. (EOLS) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Evolus, INC.?

Forward-looking statements and predictions from Evolus, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Evolus, INC.. Recent 10-Q filing on Nov 5, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.

View Evolus, INC. on SEC EDGAR

Overview

Evolus, INC. (EOLS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 5, 2025: Evolus, Inc. (EOLS) reported a significant increase in product revenue, reaching $68.967 million for the three months ended September 30, 2025, up from $60.164 million in the prior year, representing a 14.6% increase. Total net revenues for the nine months ended September 30, 2025, were $206.876 mil

Sentiment Summary

Across 30 filings, the sentiment breakdown is: 2 bullish, 27 neutral, 1 mixed. The dominant filing sentiment for Evolus, INC. is neutral.

Filing Type Overview

Evolus, INC. (EOLS) has filed 6 10-Q, 10 8-K, 2 DEF 14A, 2 10-K, 7 SC 13G/A, 3 SC 13G with the SEC between Jan 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (30)

Evolus Revenue Jumps 14.6% Amid Rising Losses, Cash Burn — 10-Q · Nov 5, 2025 Risk: high
Evolus, Inc. (EOLS) reported a significant increase in product revenue, reaching $68.967 million for the three months ended September 30, 2025, up from $60.164
Evolus Appoints New Directors, Sees Director Departure — 8-K · Sep 8, 2025 Risk: low
Evolus, Inc. announced on September 8, 2025, the departure of director Dr. David L. R. Alston. The company also announced the election of two new directors, Dr.
Evolus Q2 Revenue Soars 39%, Net Loss Narrows — 10-Q · Aug 5, 2025 Risk: medium
Evolus, Inc. reported a significant increase in product revenue for the three months ended June 30, 2025, reaching $62.5 million, up from $45.0 million in the p
Evolus CFO Departs, Interim Appointed; New Directors Elected — 8-K · Jun 6, 2025 Risk: medium
Evolus, Inc. announced on June 5, 2025, the departure of its Chief Financial Officer, Michael J. MacIntyre, effective June 14, 2025. The company also appointed
Evolus Appoints New Directors, One Departs — 8-K · May 27, 2025 Risk: low
Evolus, Inc. announced on May 23, 2025, the departure of director Dr. David L. Brown. The company also elected two new directors, Dr. Jeffrey L. Blount and Ms.
Evolus, Inc. Files Q1 2025 10-Q Report — 10-Q · May 7, 2025 Risk: low
Evolus, Inc. filed its 10-Q for the period ending March 31, 2025. The company, operating in pharmaceutical preparations, reported financial data for the first q
Evolus, Inc. Enters Material Agreement, Incurs Financial Obligation — 8-K · May 5, 2025 Risk: medium
Evolus, Inc. announced on May 5, 2025, the entry into a material definitive agreement and the creation of a direct financial obligation. The company also made a
Evolus Inc. Files 2024 Executive Compensation Details — DEF 14A · Apr 25, 2025 Risk: medium
Evolus, Inc. filed its DEF 14A on April 25, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information
Evolus, Inc. Files 2024 10-K — 10-K · Mar 4, 2025 Risk: medium
Evolus, Inc. filed its 2024 10-K on March 4, 2025, reporting on its fiscal year ending December 31, 2024. The company, based in Newport Beach, CA, operates in t
Evolus, Inc. Files 8-K on Financials — 8-K · Jan 21, 2025 Risk: low
Evolus, Inc. filed an 8-K on January 21, 2025, reporting on its results of operations and financial condition. The filing also includes financial statements and
SC 13G/A Filing — SC 13G/A · Nov 14, 2024
SC 13G/A Filing — SC 13G/A · Nov 14, 2024
SC 13G/A Filing — SC 13G/A · Nov 13, 2024
Evolus, Inc. Files Q3 2024 10-Q Financial Report — 10-Q · Nov 6, 2024 Risk: medium
Evolus, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results for the third quarter and the first nine months
Evolus, Inc. Files Q2 2024 10-Q — 10-Q · Jul 31, 2024 Risk: medium
Evolus, Inc. filed its 10-Q for the period ending June 30, 2024. The company, based in Newport Beach, CA, operates in the Pharmaceutical Preparations sector. Ke
Evolus Appoints New CMO, Elects Director — 8-K · Jul 1, 2024 Risk: low
Evolus, Inc. announced on July 1, 2024, the appointment of Dr. David J. Stark as Chief Medical Officer and the election of Ms. Sarah E. Gleason to its Board of
Evolus Announces CFO Departure, New CMO & Board Members — 8-K · Jun 11, 2024 Risk: medium
Evolus, Inc. announced on June 6, 2024, the departure of its Chief Financial Officer, Michael J. MacBride, effective June 14, 2024. The company also appointed D
Evolus, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 7, 2024 Risk: low
Evolus, Inc. (EOLS) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Evolus, Inc. filed a 10-Q report for the period ending March 31, 2024. The fili
Evolus Files 2024 Definitive Proxy Statement — DEF 14A · Apr 26, 2024 Risk: low
Evolus, Inc. filed its definitive proxy statement (DEF 14A) on April 26, 2024, for its fiscal year ending December 31, 2023. The filing outlines the company's g
Evolus Appoints New Chief Medical Officer — 8-K · Apr 3, 2024 Risk: low
Evolus, Inc. announced on April 2, 2024, the appointment of Dr. David J. Stark as Chief Medical Officer and Executive Vice President, effective April 1, 2024. D
Evolus, Inc. Signs Material Definitive Agreement — 8-K · Mar 13, 2024 Risk: medium
Evolus, Inc. announced on March 11, 2024, that it entered into a material definitive agreement. The company, headquartered in Newport Beach, California, filed a
Evolus, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 7, 2024 Risk: medium
Evolus, Inc. (EOLS) filed a Annual Report (10-K) with the SEC on March 7, 2024. Evolus, Inc. filed its 2023 Form 10-K on March 7, 2024, reporting on the fiscal
SC 13G/A Filing — SC 13G/A · Feb 14, 2024
SC 13G/A Filing — SC 13G/A · Feb 14, 2024
SC 13G Filing — SC 13G · Feb 14, 2024
SC 13G Filing — SC 13G · Feb 13, 2024
SC 13G/A Filing — SC 13G/A · Feb 13, 2024
First Manhattan Co. LLC Reports 490K Shares in Evolus, Inc. — SC 13G/A · Feb 12, 2024 Risk: low
First Manhattan Co. LLC, a Delaware-based investment firm, filed an amended SC 13G/A on February 12, 2024, disclosing its beneficial ownership in Evolus, Inc. A
BlackRock Boosts Evolus Stake to 7.0% as of Dec 31, 2023 — SC 13G · Jan 29, 2024
BlackRock Inc., a major investment firm, reported its holdings in Evolus, Inc. (pharmaceutical preparations) as of December 31, 2023. BlackRock now beneficially
Evolus 8-K Details Operations & Financial Condition — 8-K · Jan 16, 2024
Evolus, Inc. filed an 8-K on January 16, 2024, reporting on 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits.' This filing

Risk Profile

Risk Assessment: Of EOLS's 20 recent filings, 1 were flagged as high-risk, 10 as medium-risk, and 9 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Evolus, INC.'s most recent 10-Q filing (Nov 5, 2025):

Revenue: $206.876M
Net Income: $(51.771M)
EPS: N/A
Debt-to-Equity: N/A
Cash Position: $43.523M
Operating Margin: N/A
Total Assets: $218.997M
Total Debt: $247.757M

Key Executives

Dr. David L. R. Alston
Dr. Jonathan A. L. Alston
Ms. Sarah E. K. Alston
Michael J. MacIntyre
David W. R. Hall
Sarah B. Michelson
Dr. David L. Brown
Dr. Jeffrey L. Blount
Ms. Michelle L. Griffin
Dr. David J. Stark
Ms. Sarah E. Gleason
Michael J. MacBride
Ms. Michelle L. R. Smith

Industry Context

Evolus operates in the highly competitive medical aesthetics market, which is characterized by continuous innovation and increasing consumer demand for minimally invasive procedures. Key competitors include established pharmaceutical and biotechnology companies with broad portfolios. Industry trends show a growing preference for non-surgical treatments, driving market expansion but also intensifying competition for market share and product differentiation.

Top Tags

governance (4) · 10-Q (4) · pharmaceuticals (4) · financials (3) · Biotechnology (2) · Aesthetics (2) · Revenue Growth (2) · board-changes (2) · Pharmaceuticals (2) · board-election (2)

Key Numbers

Product revenue, net (Q3 2025): $68.967M — Increased from $60.164M in Q3 2024, a 14.6% rise.
Total net revenues (YTD Sep 2025): $206.876M — Increased from $187.327M in YTD Sep 2024.
Net loss (Q3 2025): $(15.737M) — Compared to $(19.170M) in Q3 2024, showing a reduced loss.
Net loss (YTD Sep 2025): $(51.771M) — Increased from $(43.629M) in YTD Sep 2024.
Cash and cash equivalents (Sep 30, 2025): $43.523M — Decreased from $86.952M at Dec 31, 2024.
Net cash used in operating activities (YTD Sep 2025): $(55.092M) — Increased from $(22.807M) in YTD Sep 2024, indicating higher cash burn.
Long-term portion of term loan (Sep 30, 2025): $145.780M — Increased from $121.506M at Dec 31, 2024, due to new financing.
Restructuring costs (Q3 2025): $1.443M — New expense incurred during the quarter.
Shares outstanding (Oct 31, 2025): 64,819,784 — Increased from 63,497,548 shares at Dec 31, 2024.
Cost of goods sold (Q3 2025): $23.126M — Increased from $18.986M in Q3 2024.
Q2 2025 Product Revenue: $62.5M — Up 38.9% from $45.0M in Q2 2024
Six-Month Product Revenue: $118.0M — Up 36.0% from $86.8M in the prior year
Q2 2025 Net Loss: -$10.2M — Improved from -$15.5M in Q2 2024
Six-Month Net Loss: -$22.1M — Improved from -$32.0M in the prior year
Q2 Product Revenue Growth: 38.9% — Year-over-year increase for the quarter

Forward-Looking Statements

{"claim":"First Manhattan Co. LLC will maintain a significant stake in Evolus, Inc. throughout 2024.","entity":"First Manhattan Co. LLC","targetDate":"December 31, 2024","confidence":"medium"}

Related Companies

ABBV · EVLS · EVOL · RVNC

Frequently Asked Questions

What are the latest SEC filings for Evolus, INC. (EOLS)?

Evolus, INC. has 30 recent SEC filings from Jan 2024 to Nov 2025, including 10 8-K, 7 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of EOLS filings?

Across 30 filings, the sentiment breakdown is: 2 bullish, 27 neutral, 1 mixed. The dominant sentiment is neutral.

Where can I find Evolus, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Evolus, INC. (EOLS) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Evolus, INC.?

Key financial highlights from Evolus, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for EOLS?

The investment thesis for EOLS includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Evolus, INC.?

Key executives identified across Evolus, INC.'s filings include Dr. David L. R. Alston, Dr. Jonathan A. L. Alston, Ms. Sarah E. K. Alston, Michael J. MacIntyre, David W. R. Hall and 8 others.

What are the main risk factors for Evolus, INC. stock?

Of EOLS's 20 assessed filings, 1 were flagged high-risk, 10 medium-risk, and 9 low-risk.

What are recent predictions and forward guidance from Evolus, INC.?

Recent forward-looking statements from Evolus, INC. include guidance on {"claim":"First Manhattan Co. LLC will maintain a significant stake in Evolus, Inc. throughout 2024.","entity":"First Ma.